Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
27
04
2022
pubmed:
7
6
2022
medline:
6
8
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Delamanid is a nitroimidazole, a novel class of drug for treating tuberculosis, and is primarily metabolized by albumin into the metabolite DM-6705. The aims of this analysis were to develop a population pharmacokinetic (PK) model to characterize the concentration-time course of delamanid and DM-6705 in adults with drug-resistant tuberculosis and to explore a potential drug-drug interaction with bedaquiline when coadministered. Delamanid and DM-6705 concentrations after oral administration, from 52 participants (of whom 26 took bedaquiline concurrently and 20 were HIV-1 positive) enrolled in the DELIBERATE trial were analyzed using nonlinear mixed-effects modeling. Delamanid PK were described by a one-compartment disposition model with transit compartment absorption (mean absorption time of 1.45 h [95% confidence interval 0.501-2.20]) and linear elimination, while the PK of DM-6705 metabolite were described by a one-compartment disposition model with delamanid clearance as input and linear elimination. Predicted terminal half-life values for delamanid and DM-6705 were 15.1 h and 7.8 days, respectively. The impact of plasma albumin concentrations on delamanid metabolism was not significant. Bedaquiline coadministration did not affect delamanid PK. Other than allometric scaling with body weight, no patients' demographics were significant (including HIV). This is the first joint PK model of delamanid and its DM-6705 metabolite. As such, it can be utilized in future exposure-response or exposure-safety analyses. Importantly, albumin concentrations, bedaquiline coadministration, and HIV co-infection (dolutegravir coadministration) did not have an effect on delamanid and DM-6705 PK.
Sections du résumé
BACKGROUND AND OBJECTIVE
Delamanid is a nitroimidazole, a novel class of drug for treating tuberculosis, and is primarily metabolized by albumin into the metabolite DM-6705. The aims of this analysis were to develop a population pharmacokinetic (PK) model to characterize the concentration-time course of delamanid and DM-6705 in adults with drug-resistant tuberculosis and to explore a potential drug-drug interaction with bedaquiline when coadministered.
METHODS
Delamanid and DM-6705 concentrations after oral administration, from 52 participants (of whom 26 took bedaquiline concurrently and 20 were HIV-1 positive) enrolled in the DELIBERATE trial were analyzed using nonlinear mixed-effects modeling.
RESULTS
Delamanid PK were described by a one-compartment disposition model with transit compartment absorption (mean absorption time of 1.45 h [95% confidence interval 0.501-2.20]) and linear elimination, while the PK of DM-6705 metabolite were described by a one-compartment disposition model with delamanid clearance as input and linear elimination. Predicted terminal half-life values for delamanid and DM-6705 were 15.1 h and 7.8 days, respectively. The impact of plasma albumin concentrations on delamanid metabolism was not significant. Bedaquiline coadministration did not affect delamanid PK. Other than allometric scaling with body weight, no patients' demographics were significant (including HIV).
CONCLUSIONS
This is the first joint PK model of delamanid and its DM-6705 metabolite. As such, it can be utilized in future exposure-response or exposure-safety analyses. Importantly, albumin concentrations, bedaquiline coadministration, and HIV co-infection (dolutegravir coadministration) did not have an effect on delamanid and DM-6705 PK.
Identifiants
pubmed: 35668346
doi: 10.1007/s40262-022-01133-2
pii: 10.1007/s40262-022-01133-2
pmc: PMC9349160
mid: NIHMS1822712
doi:
Substances chimiques
Albumins
0
Antitubercular Agents
0
Diarylquinolines
0
Nitroimidazoles
0
OPC-67683
0
Oxazoles
0
bedaquiline
78846I289Y
Banques de données
ClinicalTrials.gov
['NCT02583048']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1177-1185Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106701
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI150349
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Drug Metab Dispos. 2015 Aug;43(8):1277-83
pubmed: 26055621
Pharm Res. 1998 Sep;15(9):1463-8
pubmed: 9755901
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
Lancet Infect Dis. 2019 May;19(5):470
pubmed: 31034392
Antimicrob Agents Chemother. 2020 Dec 16;65(1):
pubmed: 33106258
Eur Respir J. 2017 Nov 16;50(5):
pubmed: 29146605
PLoS Med. 2006 Nov;3(11):e466
pubmed: 17132069
Toxicol Pathol. 1995 Mar-Apr;23(2):115-23
pubmed: 7569664
Adv Drug Deliv Rev. 2016 Jul 1;102:55-72
pubmed: 27151308
CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):682-691
pubmed: 27863179
Eur Respir J. 2018 Mar 22;51(3):
pubmed: 29545276
Int J Mol Sci. 2017 Feb 07;18(2):
pubmed: 28178199
Drug Metab Dispos. 2015 Aug;43(8):1267-76
pubmed: 26055620
N Engl J Med. 2012 Jun 7;366(23):2151-60
pubmed: 22670901
Lancet Infect Dis. 2021 Jul;21(7):975-983
pubmed: 33587897
Tuberculosis (Edinb). 2018 Jul;111:20-30
pubmed: 30029909
CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1538-1549
pubmed: 34626526
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5976-85
pubmed: 27458223